Han Chong Toh | Chief Medical Officer
Tessa Therapeutics | Singapore

Han Chong Toh, Chief Medical Officer, Tessa Therapeutics

Dr Toh Han Chong is Senior Consultant and Deputy Director, National Cancer Centre Singapore (NCCS). He is Associate Professor at the Cancer & Stem Cell Biology Program, Duke-NUS. He is former Head, Division of Medical Oncology, NCCS. Dr Toh obtained the International Baccalaureate diploma on a United World College Scholarship to Lester B. Pearson College, British Columbia, Canada. He later graduated from the University of London, UK, with an Intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, USA and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. Dr Toh is a recipient of the Senior National Clinician Scientist Award 2017 for his work on cancer biology and therapeutics, an alumni of the Harvard Business School General Management Program and is on the council of the Asia-Pacific Primary Liver Cancer Expert (APPLE) panel. He has published over 100 peer review journal papers to date in journals such as Nature Reviews Clinical Oncology, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology and Journal of Clinical Investigation. His academic interests include gastrointestinal cancers, cancer immunotherapy, cancer biology especially in liver and nasopharyngeal cancer, drug development and health policy.


Phar-East Day One @ 11:20

Awakening the immune system against cancer - Moving into the clinic

Is cancer immunotherapy the beginning of the end of cancer? Discover cases where immunotherapy can be used to treat complicated cancer cases, including leukaemia, breast cancer and more.

back to speakers